コンテンツへスキップ
Merck
  • Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis.

Solid phase microextraction, mass spectrometry and metabolomic approaches for detection of potential urinary cancer biomarkers--a powerful strategy for breast cancer diagnosis.

Talanta (2012-01-31)
Catarina L Silva, Mário Passos, José S Câmara
要旨

A sensitive assay to identify volatile organic metabolites (VOMs) as biomarkers that can accurately diagnose the onset of breast cancer using non-invasively collected clinical specimens is ideal for early detection. Therefore the aim of this study was to establish the urinary metabolomic profile of breast cancer patients and healthy individuals (control group) and to explore the VOMs as potential biomarkers in breast cancer diagnosis at early stage. Solid-phase microextraction (SPME) using CAR/PDMS sorbent combined with gas chromatography-mass spectrometry was applied to obtain metabolomic information patterns of 26 breast cancer patients and 21 healthy individuals (controls). A total of seventy-nine VOMs, belonging to distinct chemical classes, were detected and identified in control and breast cancer groups. Ketones and sulfur compounds were the chemical classes with highest contribution for both groups. Results showed that excretion values of 6 VOMs among the total of 79 detected were found to be statistically different (p<0.05). A significant increase in the peak area of (-)-4-carene, 3-heptanone, 1,2,4-trimethylbenzene, 2-methoxythiophene and phenol, in VOMs of cancer patients relatively to controls was observed. Statistically significant lower abundances of dimethyl disulfide were found in cancer patients. Bioanalytical data were submitted to multivariate statistics [principal component analysis (PCA)], in order to visualize clusters of cases and to detect the VOMs that are able to differentiate cancer patients from healthy individuals. Very good discrimination within breast cancer and control groups was achieved. Nevertheless, a deep study using a larger number of patients must be carried out to confirm the results.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
アセトン, ACS reagent, ≥99.5%
Sigma-Aldrich
酢酸, glacial, ACS reagent, ≥99.7%
Sigma-Aldrich
アセトン, suitable for HPLC, ≥99.9%
Sigma-Aldrich
酢酸, glacial, ReagentPlus®, ≥99%
Sigma-Aldrich
アセトン, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%
Sigma-Aldrich
アセトン, Laboratory Reagent, ≥99.5%
Sigma-Aldrich
2-ブタノン, ACS reagent, ≥99.0%
Sigma-Aldrich
酢酸, glacial, ≥99.99% trace metals basis
Sigma-Aldrich
4-メチル-2-ペンタノン, suitable for HPLC, ≥99.5%
Sigma-Aldrich
酢酸 溶液, suitable for HPLC
Sigma-Aldrich
2-ブタノン, suitable for HPLC, ≥99.7%
Sigma-Aldrich
酢酸, glacial, puriss., meets analytical specification of Ph. Eur., BP, USP, FCC, 99.8-100.5%
Sigma-Aldrich
4-メチル-2-ペンタノン, ACS reagent, ≥98.5%
Sigma-Aldrich
アセトン, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., ≥99.5% (GC)
Sigma-Aldrich
フェノール 溶液, BioReagent, Equilibrated with 10 mM Tris HCl, pH 8.0, 1 mM EDTA, for molecular biology
Sigma-Aldrich
1-オクタノール, ACS reagent, ≥99%
Sigma-Aldrich
アセトン, suitable for HPLC, ≥99.8%
Sigma-Aldrich
オクタン酸, ≥99%
Sigma-Aldrich
アセトン, ACS reagent, ≥99.5%
Sigma-Aldrich
1-オクタノール, suitable for HPLC, ≥99%
Sigma-Aldrich
ヘキサン酸, ≥99%
Sigma-Aldrich
1-オクタノール, ReagentPlus®, 99%
Sigma-Aldrich
デカン酸, ≥99.5%, FCC, FG
Sigma-Aldrich
グアイアコール, oxidation indicator
Sigma-Aldrich
ヘキサナール, 98%
Sigma-Aldrich
フェノール 溶液, BioReagent, Saturated with 0.01 M citrate buffer, pH 4.3 ± 0.2, for molecular biology
Sigma-Aldrich
p-シメン, 99%
Sigma-Aldrich
デカン酸, ≥98.0%
Sigma-Aldrich
2-ヘプタノン, 99%
Sigma-Aldrich
酢酸, for luminescence, BioUltra, ≥99.5% (GC)